{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.5","value":"9060"},{"groupId":"OG001","spread":"92.9","value":"13600"},{"groupId":"OG002","spread":"348","value":"29500"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received step-up doses of forimtamig 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.3 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG000","title":"Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.75 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG001","title":"Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 1.5 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG002","title":"Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population included all participants in the safety population who had PK data from at least one post-dose sample. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Up to Day 15 of Cycle 3 (1 cycle=28 days)","title":"Area Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig","type":"SECONDARY","unitOfMeasure":"nanograms*hour/milliliter (ng*hr/mL)"}